Diazyme Laboratories uses its platform enzyme technologies including enzyme cycling and Substrate-Trapping-Enzyme (STE) to develop low cost and robust diagnostic products for clinical laboratories. Diazyme’s focus is to develop enzyme based diagnostic reagents which can be used on most automated chemistry analyzers in user-friendly formats. Diazyme’s products include diagnostic blood tests for diabetes, renal and liver disease as well as cardiac and inflammatory markers, and electrolytes.
Diazyme’s patented Substrate-Trapping-Enzyme (STE) Technology® employs genetically engineered enzymes that lack catalytic activity but specifically and tightly trap their substrate or product molecules as the basis for clinical diagnostic tests. The STE Technology® is particularly suitable for small molecule detection due to its high specificity and low development cost. It is developed to replace most of the current chromatography-based and heterogeneous immunoassay based clinical diagnostic tests especially for small molecules such as vitamins, hormones and drugs. STE based test is homogenous with high throughput, low cost and can be applied on all types of automated clinic chemistry analyzers.
Enzyme Cycling Technology
Diazyme has developed a series of enzyme cycling technologies for applications in clinic diagnostic tests. Enzyme cycling based assays utilize one or more coupled enzymatic reactions to convert one of the enzyme reaction products back to the enzyme substrate so as to form a substrate-product-substrate (S-P-S) conversion cycle with a concomitant formation of a reaction by-product that is detected at n times higher sensitivity at the end of n times the S-P-S cycle. A summary of the Diazyme enzyme cycling technologies from type I to type III, and method A to method E is presented in the published article titled “Enzyme Cycling Methods and Applications in Clinic Diagnostics” (authored by Dr. Chong Yuan, 2006, click here to open the full article).